268547-53-1

Basic information

• Product Name: 3-BROMO-7-CHLORO-5-METHYL-1H-PYRAZOLO[4,3-B]PYRIDINE
• Synonyms: 3-BROMO-7-CHLORO-5-METHYL-1H-PYRAZOLO[4,3-B]PYRIDINE
• CAS NO: 268547-53-1
• Molecular Formula: C₇H₅BrClN₃
• Molecular Weight: 246.49
• Mol File: 268547-53-1.mol

Chemical Properties

• Boiling Point: 373.4±37.0 °C(Predicted)
• Appearance: /
• Density: 1.857±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 6.91±0.40(Predicted)
• CAS DataBase Reference: 3-BROMO-7-CHLORO-5-METHYL-1H-PYRAZOLO[4,3-B]PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-7-CHLORO-5-METHYL-1H-PYRAZOLO[4,3-B]PYRIDINE(268547-53-1)
• EPA Substance Registry System: 3-BROMO-7-CHLORO-5-METHYL-1H-PYRAZOLO[4,3-B]PYRIDINE(268547-53-1)

Safety Data

• Hazardous Substances Data: 268547-53-1(Hazardous Substances Data)

Upstream product

• 268547-52-0 5-methyl-1H-pyrazolo[4,3-b]pyridine-7-ol 
• 94220-38-9 7-chloro-5-methyl-1H-pyrazolo[4,3-b]-pyridine 

Downstream Products

• 866141-78-8 1-[4-(6-cyclopropylmethyl-7-ethyl-4-methyl-7,8-dihydro-6H-1,3,6,8a-tetraaza-acenaphthylen-2-yl)-3-trifluoromethyl-phenyl]-ethanone 
• 866141-79-9 6-cyclopropylmethyl-7-ethyl-2-(4-isopropenyl-2-trifluoromethyl-phenyl)-4-methyl-7,8-dihydro-6H-1,3,6,8a-tetraaza-acenaphthylene 
• 884503-95-1 7-benzyloxy-3-bromo-5-methyl-1H-pyrazolo[4,3-b]pyridine 

Relevant articles and documents

CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a mammals, such as stroke. The CRF receptor antagonists of this invention have the following structure: and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2n, R5, Ar, and Het are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists

Antagonists of the corticotropin-releasing factor (CRF) neuropeptide should prove to be effective in treating stress and anxiety-related disorders. In an effort to identify antagonists with improved physicochemical properties, new tricyclic CRF1/sub

CRF receptor antagonists and methods relating thereto

CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers and pharmaceutically acceptable salts thereof, wherein n, m, A, B, C, R, R1, R2and Ar are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same

CRF receptor antagonists and methods relating thereto

CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers and pharmaceutically acceptable salts thereof, wherein n, m, A, B, C, R, R1, R2and Ar are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same